Milan, Italy

Mario Micciarelli

This inventor holds 1 USPTO granted patent. Top assignee: Lark S.p.a.. Active years: 1980.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1980

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mario Micciarelli

Introduction

Mario Micciarelli is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-inflammatory agents. His work has led to advancements that may benefit various medical applications.

Latest Patents

Micciarelli holds a patent for "16,17-Pyrazolino- and 16,17-isopyrazolino-1,4-pregnadiene derivatives." This patent describes the preparation of new derivatives that are useful as anti-inflammatory agents for both topical and systemic administration. The patent also discloses an analogy process for the preparation of these derivatives and highlights the surprising conversion of 16,17-pyrazolino-1,4-pregnadiene derivatives to their isopyrazolino counterparts. The results of pharmacological comparative trials of some new products from this invention against fluocinolone acetonide are also reported.

Career Highlights

Mario Micciarelli is associated with Lark S.p.a., where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding and application of pyrazolino derivatives in medicine.

Collaborations

Micciarelli collaborates with Gaetano Palladino, contributing to the research and development efforts at Lark S.p.a. Their partnership has fostered a productive environment for innovation in the pharmaceutical industry.

Conclusion

Mario Micciarelli's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for new treatments and advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…